HIF1A and neoplasm: Ongoing research focuses on small-molecule inhibitors of HIF-1α, nanoparticle-mediated drug delivery systems for targeted inhibition, and metabolic reprogramming strategies to mitigate hypoxia-induced tumor aggressiveness [15].